Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
Key Points
Key points are not available for this paper at this time.
Abstract
clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and NCT01844505 (CheckMate 067).
Long et al. (Thu,) studied this question.
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
2008 · 166 citations